NCT01239108

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Astex Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.

Detailed description

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects with Relapsed/Refractory Leukemias

Conditions

• Relapsed/Refractory Leukemias

Interventions

Type	Name	Description
DRUG	SGI-1776	SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.

Timeline

• Start date: 2010-10-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2010-11-11
• Last updated: 2024-08-02

Locations

1 site across 1 country: United States